PAM

Across TCGA pan-cancer cohorts, PAM mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PAM data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PAM mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PAM expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, LUAD, and UCEC are the cancer types where PAM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	23	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	14	view →
UCEC	OS	Median	II,III,IV	0.628	1.000	.013	12	view →
LSCC	OS	Median	All	0.731	0.904	.003	10	view →
PDAC	OS	Quartile	II,III,IV	1.000	0.694	.002	9	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PAM–CCRCC (DFS)

Open the CCRCC breakdown →